Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to -$11.6 million.

  • Akebia Therapeutics' Other Working Capital Changes fell 24718.97% to -$11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.1 million, marking a year-over-year increase of 574.35%. This contributed to the annual value of -$8.9 million for FY2024, which is 2488.39% up from last year.
  • Akebia Therapeutics' Other Working Capital Changes amounted to -$11.6 million in Q3 2025, which was down 24718.97% from $7.7 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Other Working Capital Changes ranged from a high of $37.1 million in Q3 2021 and a low of -$11.6 million during Q3 2025
  • Moreover, its 5-year median value for Other Working Capital Changes was -$2.4 million (2023), whereas its average is -$181000.0.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first surged by 68196.64% in 2021, then crashed by 51372.55% in 2024.
  • Over the past 5 years, Akebia Therapeutics' Other Working Capital Changes (Quarter) stood at -$6.4 million in 2021, then soared by 406.1% to $19.5 million in 2022, then plummeted by 109.22% to -$1.8 million in 2023, then dropped by 16.26% to -$2.1 million in 2024, then crashed by 453.21% to -$11.6 million in 2025.
  • Its Other Working Capital Changes was -$11.6 million in Q3 2025, compared to $7.7 million in Q2 2025 and -$2.2 million in Q1 2025.